Table 1.
The relationship between LINC00673 and clinicopathologic characteristics in the validated cohort
| Clinicopathologic characteristics | High expression (%) | Low expression (%) | X2 | P |
|---|---|---|---|---|
| Age | 0.122 | 0.726 | ||
| ≤ 60 | 18 (81.8) | 10 (76.9) | ||
| > 60 | 4 (18.2) | 3 (23.1) | ||
| Tumor size | 1.301 | 0.522 | ||
| < 2 cm | 10 (45.5) | 7 (53.8) | ||
| 2-5 cm | 10 (45.5) | 6 (46.2) | ||
| > 5 cm | 2 (9) | 0 (0) | ||
| Lymph node metastasis | 4.609 | 0.032* | ||
| NO | 7 (31.8) | 9 (69.2) | ||
| YES | 15 (68.2) | 4 (30.8) | ||
| Clinical stage | 6.655 | 0.010* | ||
| I-II | 7 (31.8) | 10 (76.9) | ||
| III-IV | 15 (68.2) | 3 (23.1) | ||
| Estrogen receptor | 0.530 | 0.467 | ||
| Negative | 8 (36.3) | 5 (50) | ||
| Positive | 14 (63.6) | 5 (50) | ||
| Progesterone receptor | 0.057 | 0.811 | ||
| Negative | 10 (45.5) | 5 (50) | ||
| Positive | 12 (54.5) | 5 (50) |
*
P < 0.05.